The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Open accessAbstract
BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both insulin glargine U100 and insulin degludec have demonstrated cardiovascular safety in dedicated CVOTs (207,208).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [208]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“ORIGIN reported a 1.6 kg gain over 6 years with insulin glargine [46].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [46]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1800]
Experimental — accuracy not yet measuredIn the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [21]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [146]
In the citing paper
“In the only RCT of insulin vs. placebo [ORIGIN, 12 537 people with CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or T2DM (i.e.not in patients with HF)], insulin was not associated with higher rates of HF hospitalization than placebo.187”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [187]
In the citing paper
“Lowering glucose without addressing the vascular effects of insulin resistance may be insufficient to reduce risk of cardiovascular events.”
From The Vasculature in Prediabetes (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 701–800 of 999
Lee, Y., Han, K., Kim, B., Choi, M. S., Park, J., Kim, M., Jin, S., Hur, K. Y., Kim, G., & Kim, J. H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13539 · Cited by 17
The impact of diabetes on heart failure development: The cardio-renal-metabolic connection
Valensi, P. E., Prévost, G., Pinto, S., Halimi, J., & Donal, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108831 · Cited by 18
Goldfine, A. B., Phua, E.-J., & Abrahamson, M. J. (2014) · Circulation · doi:10.1161/circulationaha.113.006634 · Cited by 16
Goldman, J. D., & Trujillo, J. M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017717281 · Cited by 16
Frías, J. P., DEX, T. A., Roberts, M., & Kaplan, A. P. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0547-5 · Cited by 16
Therapeutic Challenges in Diabetes Prevention: We Have Not Found the “Exercise Pill”
Srinivasan, S., & Florez, J. C. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.146 · Cited by 15
Mamza, J., Rajnikant, M., Donnelly, R., & IDRIS, I. R. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116687102 · Cited by 15
Cardiovascular disease leads to a new algorithm for diabetes treatment
Rodriguez, V., Weiss, M. C., WEINTRAUB, H. S., Goldberg, I. J., & Schwartzbard, A. Z. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.004 · Cited by 15
Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes
Chatterjee, S., Khunti, K. K., & Davies, M. J. (2019) · Drugs · doi:10.1007/s40265-018-1048-6 · Cited by 15
Clinical aspects of heart failure in individuals with diabetes
Bowes, C. D., Lien, L. F., & Butler, J. (2019) · Diabetologia · doi:10.1007/s00125-019-4958-2 · Cited by 15
Sohn, M., Frías, J. P., & Lim, S. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15251 · Cited by 16
Liebl, A., Jones, S., Goday, A., Benroubi, M., Castell, C., Haupt, A., Nicolay, C., & Smith, H. T. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0009-4 · Cited by 15
Mata‐Cases, M., Artola, S., Escalada, J., Loiola, P. E., Ferrer-García, J. C., Fornos, J. A., Girbés, J., & Rica, I. (2014) · Revista Clínica Española · doi:10.1016/j.rce.2014.10.012 · Cited by 16
Roussel, R., Natali, A., Balkau, B., Højlund, K., Sánchez, G., Nolan, J. J., Mari, A., Kozàkovà, M., & Bonnet, F. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000842 · Cited by 15
Holden, S. E. (2016) · Endocrine development · doi:10.1159/000439410 · Cited by 15
Porcellati, F., Lin, J., Lucidi, P., Bolli, G. B., & Fanelli, C. G. (2017) · Medicine · doi:10.1097/md.0000000000006022 · Cited by 14
Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0783-4 · Cited by 16
Varying Effects of Body Mass Index and Mortality in Different Risk Groups
Lamelas, P. M., Schwalm, J.-D., Leong, D. P., Jolly, S. S., Mehta, S. R., Bangdiwala, S. I., & Yusuf, S. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.06.038 · Cited by 15
Kim, D., Ahn, B., Kim, Y. S., Hur, D. Y., Yang, J. W., Park, G. B., Jang, J. E., Lee, E. J., Kwon, M. J., Kim, T. N., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2376512 · Cited by 15
Physico-chemical stability of co-formulation of PEGylated human amylin with insulin
Sinésia, C., do Nascimento, C. V. M. F., Lacativa, P. G. S., & Lima, L. M. T. R. (2019) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2019.1621896 · Cited by 15
Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome
Cavallari, I., Maddaloni, E., Gragnano, F., Patti, G., Antonucci, E., Calabrò, P., Cirillo, P. L., Gresele, P., Palareti, G., Pengo, V., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02640-z · Cited by 15
Longato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01414-3 · Cited by 15
Liu, J., & Hu, X. (2022) · Diabetes and Vascular Disease Research · doi:10.1177/14791641221093175 · Cited by 15
Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update
Koniari, I. C., Velissaris, D., Kounis, N. G., Koufou, E., Artopoulou, E., GREGORIO, C. D., Mplani, V., Paraskevas, T., Tsigkas, G., Hung, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164660 · Cited by 16
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases
Donovan, K., Herrington, W. G., Paré, G., Pigeyre, M., Haynes, R., Sardell, R. J., Butterworth, A. S., Folkersen, L., Gustafsson, S., Wang, Q., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05080422 · Cited by 20
Identifying prediabetes – Is it beneficial in the long run?
Ghody, P., Shikha, D., Karam, J., & Bahtiyar, G. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.03.022 · Cited by 18
Lundby‐Christensen, L., Vaag, A. A., Tarnow, L., Almdal, T., Lund, S. S., Wetterslev, J., Gluud, C. N., Boesgaard, T. W., Wiinberg, N., Perrild, H., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-008377 · Cited by 15
White, J. R. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.86 · Cited by 15
New Insulins, Biosimilars, and Insulin Therapy
Danne, T., Heinemann, L., & Bolinder, J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.2504 · Cited by 15
Maggioni, A. P., Calabria, S., Rossi, E., & Martini, N. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.108 · Cited by 15
Mosleh, W., Sharma, A., Sidhu, M. S., Page, B. J., Sharma, U. C., & Farkouh, M. E. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6729-y · Cited by 15
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis
Grenet, G., Ribault, S., Nguyen, G. B., Glais, F., Metge, A., Linet, T., Kassaï, B., Cornu, C., Bejan‐Angoulvant, T., Erpeldinger, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217701 · Cited by 15
Kotsis, V., Jordan, J., Stabouli, S., Antza, C., Micić, D., Jelaković, B., Schlaich, M. P., Nilsson, P. M., Kreutz, R. H., Mancia, G., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002279 · Cited by 14
Lessons from SAVOR and EXAMINE: Some important answers, but many open questions
Schernthaner, G., & Sattar, N. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.02.011 · Cited by 15
Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox
Green, J. B. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2767 · Cited by 14
Azim, S., Baker, W. L., & White, W. B. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0541-0 · Cited by 14
Gerstein, H. C., Ramasundarahettige, C. F., Avezum, A., Basile, J., Conget, I., Cushman, W. C., Dagenais, G. R., Franek, E., Lakshmanan, M. C., Lanas, F. T., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01594-6 · Cited by 15
Glargine and Cancer: Can We Now Suggest Closure?
Owens, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-1968 · Cited by 14
Mata‐Cases, M., Artola, S., Escalada, J., Loiola, P. E., Ferrer-García, J. C., Fornos, J. A., Girbés, J., & Rica, I. (2015) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.12.001 · Cited by 16
Zhang, X., Sheng, X., Miao, T., Yao, K., & Yao, D. (2018) · Endocrine Research · doi:10.1080/07435800.2018.1522641 · Cited by 14
Martínez, J. J. G. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.03.005 · Cited by 15
Novel Biomarkers for Change in Renal Function in People With Dysglycemia
Gerstein, H. C., Paré, G., McQueen, M., Lee, S. F., Bangdiwala, S. I., Kannt, A., & Hess, S. (2019) · Diabetes Care · doi:10.2337/dc19-1604 · Cited by 14
Giuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Diabetes mellitus and multiple myeloma; common features of two distinct entities
Tentolouris, A., Ntanasis‐Stathopoulos, I., Eleftheriadou, I., Malandrakis, P., Tzeravini, E., & Gavriatopoulou, M. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3535 · Cited by 14
The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin
Shaefer, C. F., & Anderson, J. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1103640 · Cited by 14
Obesity, Type 2 Diabetes and Beta Cell Failure: An Asian Perspective
Saisho, Y. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.s1-008 · Cited by 14
Revisiting the Diabetes-Heart Failure Connection
Wallner, M., Eaton, D., von Lewinski, D., & Sourij, H. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1116-z · Cited by 14
Diabetes: the place of new therapies
Dhatariya, K. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818807599 · Cited by 14
Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2019)
Clodi, M., Abrahamian, H., Aberer, F., Bräuer, A., Aydinkoc-Tuzcu, K., Brath, H., Brix, J. M., Drexel, H., Fasching, P., Feder, A., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1471-z · Cited by 14
RSSDI consensus recommendations on insulin therapy in the management of diabetes
(extended), E. P., Chawla, R., Makkar, B. M., Aggarwal, S., Bajaj, S., Das, A. K., Ghosh, S. K., Gupta, A., Gupta, S., Jaggi, S., et al. (2019) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-019-00783-6 · Cited by 15
Heise, T., DONNELLY, C. M., Barve, A. J., & Aubonnet, P. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13919 · Cited by 15
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R. M., Blüher, M., Böhm, M., Brosius, F. C., Carr, R. D., Ceriello, A., Forst, T. M., Giorgino, F., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01481-0 · Cited by 15
Lamy, A. L., Tong, W., Jung, H. S., Gafni, A., Singh, K., Tyrwhitt, J., Yusuf, S., & Gerstein, H. C. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.02.012 · Cited by 14
Type 2 Diabetes Prevention: Implications of Hemoglobin A1c Genetics
Leong, A., & Meigs, J. B. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.351 · Cited by 13
Basal Insulin and Cardiovascular and Other Outcomes
Vigneri, R., Vigneri, P. G., & Frittitta, L. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1210553 · Cited by 14
Aroda, V. R., Arulandu, J. R., & Cannon, A. J. (2018) · Clinical Diabetes · doi:10.2337/cd17-0065 · Cited by 13
Pigeyre, M., Sjaarda, J., Mao, S., Chong, M., Hess, S., Yusuf, S., Gerstein, H. C., & Paré, G. (2019) · Diabetes Care · doi:10.2337/dc18-2444 · Cited by 13
Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review
Prentza, V., Pavlidis, G., Ikonomidis, I., Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Thymis, J., Palaiodimou, L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195786 · Cited by 14
Cardiovascular effects of basal insulins
Mannucci, E., Giannini, S., & Dicembrini, I. (2015) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s43300 · Cited by 14
New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?
Jayawardene, D., Ward, G. M., O'Neal, D. N., Theverkalam, G., MacIsaac, A. I., & MacIsaac, R. J. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.05.007 · Cited by 13
The Year in Cardiology 2012: focus on cardiovascular disease prevention
Charakida, M., Masi, S., & Deanfield, J. E. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs429 · Cited by 14
Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin
Fießelmann, A., Wiesner, T., Fleischmann, H., & Bramlage, P. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0862-0 · Cited by 13
Intensive Therapy in Newly Diagnosed Type 2 Diabetes: Results of a 6-Year Randomized Trial
Harrison, L., ADAMS-HUET, B. A., Li, X., Raskin, P., & Lingvay, I. (2014) · Journal of Investigative Medicine · doi:10.2310/jim.0000000000000068 · Cited by 14
Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes
Chi, C., SNAITH, J. R., & Gunton, J. E. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.02.030 · Cited by 13
Russo, G. T., Giorda, C. B., Cercone, S., Cosmo, S. D., Nicolucci, A., Cucinotta, D., & the BetaDecline Study Group (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3016 · Cited by 13
Individuals With Prediabetes Display Different Age-Related Pathophysiological Characteristics
Fiorentino, T. V., Pedace, E., Succurro, E., Andreozzi, F., Perticone, M., Sciacqua, A., Perticone, F., & Sesti, G. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02610 · Cited by 13
Insuficiencia cardiaca y diabetes: la confrontación de dos grandes epidemias del siglo xxi
Formiga, F., Camafort, M., & Carrasco-Sánchez, F. J. (2019) · Revista Clínica Española · doi:10.1016/j.rce.2019.01.009 · Cited by 13
Pinto, L. C. F., Rados, D. R. V., Remonti, L. R., Viana, L. V., Pulz, G. T. C., Carpena, M. P., Borges, R. P., Marobin, R., Beretta, M. V., Pedrollo, E. F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa534 · Cited by 13
Rapoport, M. J., Chetrit, A., Cantrell, D., Novikov, I., Roth, J., & Dankner, R. S. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001981 · Cited by 15
Gallwitz, B., & Bretzel, R. G. (2013) · Diabetes Care · doi:10.2337/dcs13-2012 · Cited by 14
The Prediabetes Detection and Physical Activity Intervention Delivery (PRE-PAID) Program
Rowan, C. P., Riddell, M. C., & Jamnik, V. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.09.003 · Cited by 14
Wieringa, T. H., de Wit, M., Twisk, J. W. R., & Snoek, F. J. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000548 · Cited by 13
Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2
Arps, K. E., Pallazola, V. A., Cardoso, R. N., Meyer, J., Jones, R., Latina, J. M., Gluckman, T. J., Stone, N. J., Blumenthal, R. S., & McEvoy, J. W. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.031 · Cited by 13
Suzuki, J., Yamakawa, T., Oba, M. S., Nagakura, J., Shigematsu, E., Tamura, H., Takahashi, K., Okamoto, Y., Sakamoto, R., Shinoda, M., et al. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0309 · Cited by 13
CHILTON, R. J., Dungan, K. M., Shubrook, J. H., & Umpierrez, G. E. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.09.008 · Cited by 13
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 15
Aktuelle Therapie des Typ-2-Diabetes
Schernthaner, G., & Schernthaner, G.-H. (2012) · Der Internist · doi:10.1007/s00108-012-3203-6 · Cited by 12
for the ACCORD Group of Investigators, Punthakee, Z., Miller, M. E., Simmons, D. L., Riddle, M. C., Ismail‐Beigi, F., Brillon, D. J., Bergenstal, R. M., Savage, P. J., HRAMIAK, I. M., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3318-5 · Cited by 12
Antidiabetic agents and cardiovascular outcomes in patients with heart diseases
Cheng, J. W. M., Badreldin, H. A., Patel, D. K., & Bhatt, S. H. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1284052 · Cited by 12
Lentjes, M. A. H., Keogh, R. H., Welch, A. A., Mulligan, A. A., Luben, R., Wareham, N. J., & Khaw, K. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017471 · Cited by 12
Bala, C. G., Rusu, A., Ciobanu, D. M., Craciun, A. E., & Román, G. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s162086 · Cited by 12
Lessey, G., Stavropoulos, K., & Papademetriou, V. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s203925 · Cited by 13
Carrasco-Sánchez, F. J., Rodríguez, J. M. F., Ena, J., Gómez‐Huelgas, R., & Carretero‐Gómez, J. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.06.005 · Cited by 12
Song, X., Saito, N., Morimoto, T., Taniguchi, T., Shiomi, H., Andò, K., Nagao, K., Kanamori, N., Murata, K., Kitai, T., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0681 · Cited by 12
Chan, J. C. N., Aschner, P. J., Owens, D. R., Picard, S., Vincent, M., Dain, M., Pilorget, V., Loizeau, V., Echtay, A. S., & Fonseca, V. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.08.007 · Cited by 12
The path to approval of new drugs for diabetes
Rendell, M. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.770470 · Cited by 12
Nyström, T., Holzmann, M. J., & Sartipy, U. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002411 · Cited by 12
Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
Boccara, F., Dent, R. E., Ruilope, L. M., & Valensi, P. E. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0586-8 · Cited by 14
Asleh, R., Sheikh‐Ahmad, M., Briasoulis, Α., & Kushwaha, S. S. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9666-8 · Cited by 12
Endpoints in diabetes cardiovascular outcome trials
Patel, T. M., Tesfaldet, B., Chowdhury, I., Kettermann, A. E., Smith, J. P., Pucino, F., & Almario, E. N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31184-x · Cited by 12
Blood Glucose Management of Type 2 Diabetes in the Older People
Chen, W.-C., Lee, C.-C., Chien, M.-N., Liu, S.-C., Wang, C., & Yang, W. (2018) · International journal of gerontology · doi:10.1016/j.ijge.2018.05.008 · Cited by 12
Koufakis, T., Karras, S. Ν., Zebekakis, P. E., Ajjan, R., & Kotsa, K. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1526278 · Cited by 12
Aragon, K. G., Elmaoued, A. A., Pham, N.-Y. T., Conklin, J. R., & Ray, G. M. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000266 · Cited by 12
Pradhan, R., Yin, H., Yu, O. H. Y., & Azoulay, L. (2019) · Drug Safety · doi:10.1007/s40264-019-00892-5 · Cited by 12
Carrasco-Sánchez, F. J., Rodríguez, J. M. F., Ena, J., Gómez‐Huelgas, R., & Carretero‐Gómez, J. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2020.06.009 · Cited by 15
Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”
Manolis, A. S., Manolis, T. A., & Manolis, A. S. (2018) · Drugs · doi:10.1007/s40265-018-0985-4 · Cited by 12
Metwally, A. A., Perelman, D., Park, H., Wu, Y., Jha, A., Sharp, S. A., Celli, A., Ayhan, E. M., Abbasi, F., Gloyn, A. L., et al. (2024) · medRxiv · doi:10.1101/2024.07.20.24310737 · Cited by 12
Exercise and inactivity as modifiers of β cell function and type 2 diabetes risk
Hall, L. G., Thyfault, J. P., & Johnson, J. D. (2023) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00472.2022 · Cited by 15
Niu, S., Alkhuzam, K. A., Guan, D., Jiao, T., Shi, L., Fonseca, V. A., Laiteerapong, N., Ali, M. K., Schatz, D., Guo, J. S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15332 · Cited by 11
Management of the Patient With Diabetes and Coronary Artery Disease: A Contemporary Review
Raymond, T. E., Raymond, R. E., & Lincoff, A. M. (2013) · Future Cardiology · doi:10.2217/fca.13.22 · Cited by 11
Metadata
- Authors
- The ORIGIN Trial Investigators
- Affiliations
- Population Health Research Institute (CA)
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 319-328
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975663485
- Semantic Scholar
- 695c6a8e398d66ae418b143a3491ad91d28443bb
- Cited by
- 1,636
- References
- 29
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 76 · 2023: 86 · 2022: 82 · 2021: 108 · 2020: 101 · 2019: 139 · 2018: 155 · 2017: 152 · 2016: 155 · 2015: 132 · 2014: 168 · 2013: 147 · 2012: 53
- FWCI
- 128.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Oxford
- AFA Försäkring
- Hjärt-Lungfonden
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- basal insulin, insulin glargine, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, cardiovascular outcomes, myocardial infarction, stroke, heart failure, omega-3 fatty acids, hypoglycemia, weight gain, cancer risk, microvascular outcomes, cardiovascular risk factors, revascularization, hospitalization, new-onset diabetes
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Fasting, Female, Follow-Up Studies, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
